Cheng Zhong & Kurt Hoeprich
Business Development Director, Capsugel Lonza; Vice President Global Sales
Cheng Zhong joined Capsugel China in 1992 as a Business Analyst, and has worked in a number of finance roles of increasing responsibility within the legacy Capsugel organization, including positions in Japan and the United States. As of 2018, Cheng is Director of Business Development for the capsule business of Lonza Pharma Biotech, as well as Board Director for the Suzhou plant and General Manager for the Suzhou Joint Venture. Kurt Hoeprich joined Lonza in 2015 and has worked in a number of roles of increasing responsibility within the global Sales organization handling both Biologics and Small molecule offerings. Prior to Lonza, Kurt headed the Pharma API business for Albemarle managing cGMP custom synthesis and a portfolio of generic APIs. In the biologics area, Kurt previously worked for the Dow Chemical Company, leading the commercialization of the Pfenex® microbial expression platform. Currently, Kurt serves as Vice President, Sales for the API and Drug Formulation & Delivery Systems Business units within the Chemical Division of Lonza Pharma & Biotech. This division enables Lonza’s customers to successfully develop and manufacture both API and dosage forms of new and existing small molecule therapeutics for patients by employing innovation in custom development and manufacturing across multiple technologies. Kurt has a BSc in Biochemistry and is based in the United States. Cheng has a degree in industry management engineering from Hangzhou Dianzi University, China, and is a Certified Public Accountant of Canada (CPA). He is currently based in Suzhou, China.